Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Merck & Co. launches Nexplanon in U.S.

Nov. 10, 2011

EC grants marketing authorization to orphan drug for adrenal insufficiency in adults

Nov. 9, 2011

Lilly and Amylin reach agreement to terminate diabetes alliance

Nov. 9, 2011

Presentations provide further phase II data on lesinurad in gout

Nov. 9, 2011

Recordati's Normosang approved in Russia

Nov. 8, 2011

Novo Nordisk reports results from Japanese phase IIIa trial of DegludecPlus

Nov. 8, 2011

Evolva clear to begin phase IIa development of EV-077 in diabetic complications

Nov. 8, 2011

NPS Pharmaceuticals reports topline results from phase III REPLACE study

Nov. 8, 2011

Synageva BioPharma and Trimeris complete merger

Nov. 8, 2011

Arena Pharmaceuticals patents new molecules for type 2 diabetes and obesity

Nov. 7, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...